Core Viewpoint - Anteris Technologies Global Corp. announced a significant capital raise, leading to a 52.17% increase in share price during after-hours trading, reaching $8.75, following a regular session close of $5.75, which was up 12.52% [1]. Group 1: Capital Raise Details - The company plans to conduct a $200 million underwritten public offering of common stock, with underwriters having a 30-day option to purchase an additional $30 million in shares at the offering price [2]. - Anteris has also agreed to sell up to $90 million in common stock to Medtronic plc through a private placement, with Medtronic set to acquire between 16% and 19.99% of shares outstanding after the public offering [3]. Group 2: Use of Proceeds - Proceeds from the capital raise will be utilized to support the DurAVR Transcatheter Heart Valve global pivotal trial for patients with severe aortic stenosis, as well as to expand manufacturing capacity and development for v2vmedtech, inc. [5]. Group 3: Trading Metrics and Analysis - Anteris has a market capitalization of $236.89 million, with its stock trading within a 52-week range of $2.34 to $8.79. Over the past 12 months, the stock has seen a decline of 2.21%, indicating ongoing challenges for the company [6]. - The stock is currently positioned at 52.9% of its 52-week range, nearing yearly highs, and has a Relative Strength Index (RSI) of 66.01, suggesting a positive price trend across all time frames [6][7].